Press release

07/06/2022

Phost'in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona

Montpellier, France – June 2022, 07th
Read more
09/03/2022

Phost'in Therapeutics joins TechShare 2022, Euronext's paneuropean Pre-IPO training program

Montpellier, France – Mars 2022, 09th
Read more
11/09/2020

Phost’in Therapeutics announces €2.5m funding from Bpifrance to support regulatory and early clinical development of its First-In-Class N-Glycosylation Inhibitor

Montpellier, France – Sept 2020, 11th
Read more
17/06/2020

Phost'in Therapeutics strengthens management with appointment of veteran lifescience executives Dr. Alain Herrera and Pr. Bernard Pau

Montpellier, France – June 2020, 17th
Read more

In the news

25/04/2020

€10M Series A Boosts Cancer Immunotherapy Hitting Tumor Sugar Coating

LABIOTECH.eu – April 2020, 22nd
Read more
24/04/2020

Phost'in Therapeutics normalise la glycosylation des cellules tumorales

Les Echos – April 2020, 24th
Read more
22/04/2020

Phost’In Therapeutics lève 10,3 M€ et démarre une étude clinique contre le cancer

La Tribune – Objectif LR – April 2020, 22nd
Read more
14/11/2019

Karine Chorro, entrepreneuse en quête de sens

Le Journal Toulousain, Nov. 2019, 14th
Read more